Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

G-CSF for Imatinib-induced neutropenia

Leukemia volume 17, pages 805–807 (2003)Cite this article

TO THE EDITOR

Chronic myeloid leukemia (CML) is caused by the bcr/abl tyrosine kinase, the product of the Philadelphia chromosome (Ph). Imatinib mesylate (Glivec®, Novartis, Switzerland, formerly STI571) selectively inhibits the bcr/abl tyrosine kinase and has shown significant activity in CML patients.1,2,3

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530–3539.

    Article  CAS  Google Scholar 

  2. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928–1937.

    Article  CAS  Google Scholar 

  3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–652.

    Article  CAS  Google Scholar 

  4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038–1042.

    Article  CAS  Google Scholar 

  5. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM . Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85(12): 3636–3645.

    CAS  PubMed  Google Scholar 

  6. Mauro MJ, O'Dwyer ME, Kurilik G, Blasdel C, Farnsworth M, Fong D et al. Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib Mesylate (STI571). Blood 2001; 98(11): 139a.

    Google Scholar 

  7. Marin D, Bua M, Marktel S, Chase A, Udom C, Armstrong L et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of Interferon-alfa defines four different prognostic groups. Blood 2001; 98(11): 846a.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutic Hematology, University Hospital, Basel, Switzerland

    D Heim & A Gratwohl

  2. Diagnostic Hematology, University Hospital, Basel, Switzerland

    M Ebnöther, S Meyer-Monard, D Tsakiris & A Tichelli

  3. Novartis Pharma Schweiz AG, Berne, Switzerland

    M Linn

Authors
  1. D Heim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ebnöther
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Meyer-Monard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Tsakiris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Linn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Tichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heim, D., Ebnöther, M., Meyer-Monard, S. et al. G-CSF for Imatinib-induced neutropenia. Leukemia 17, 805–807 (2003). https://doi.org/10.1038/sj.leu.2402869

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402869

This article is cited by

Search

Advanced search

Quick links